Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD3/MUC1-armed cytokine induced killer cells - Benhealth Biopharmaceutical

Drug Profile

Anti-CD3/MUC1-armed cytokine induced killer cells - Benhealth Biopharmaceutical

Alternative Names: Activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody; Anti-CD3/MUC1 antibody-armed PD-1 inhibitor-induced cytokine-induced killer cells; Anti-CD3/MUC1-armed PD-1 inhibitor-induced CIK cells; PD-1 activated CIK armed with anti-CD3/Anti-MUC1 bispecific antibody

Latest Information Update: 03 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Benhealth Biopharmaceutical
  • Class Bispecific antibodies; Cell therapies; Drug conjugates; Immunotherapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Pancreatic cancer; Renal cancer

Most Recent Events

  • 12 Apr 2018 Phase-II clinical trials in Pancreatic cancer (Late-stage disease) in China (unspecified route) (NCT03509298)
  • 10 Apr 2018 Phase-II clinical trials in Renal cancer (Second-line therapy or greater, Late-stage disease) in China (unspecified route) (NCT03540199)
  • 05 Apr 2018 Phase-II clinical trials in Gastric cancer (Late-stage disease) in China (unspecified route) (NCT03554395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top